Plasma syndecan-1 concentration as a biomarker for endothelial glycocalyx degradation in septic adult horses.
Authors: Hobbs Kallie J, Johnson Philip J, Wiedmeyer Charles E, Schultz Loren, Foote Christopher A
Journal: Equine veterinary journal
Summary
# Editorial Summary: Plasma Syndecan-1 as a Sepsis Biomarker in Horses The endothelial glycocalyx—the carbohydrate-rich layer lining blood vessel walls—undergoes significant degradation during sepsis, releasing soluble markers into circulation that may aid clinical diagnosis and prognostication. Hobbs and colleagues conducted a retrospective cohort study of 191 adult horses stratified into three groups (healthy controls, non-septic illness, and septic cases) to investigate whether plasma syndecan-1, a well-established glycocalyx degradation product in human and small animal sepsis, could serve as a useful biomarker in equine practice. Septic horses (Group 3) demonstrated markedly elevated syndecan-1 concentrations (mean 50.73 μg/ml) compared with both healthy controls and clinically ill non-septic horses (15.69 and 16.88 μg/ml respectively), with no meaningful difference between the latter two groups, suggesting syndecan-1 specifically reflects septic pathology rather than general systemic inflammation. Whilst the study's retrospective design and single measurement timepoint limit definitive conclusions about prognostic utility, the findings establish that endothelial glycocalyx degradation can be quantified in equine blood and merit investigation as a potential diagnostic aid in horses where sepsis diagnosis remains challenging. Future prospective studies examining syndecan-1 across multiple timepoints, alongside clinical outcomes, could determine its value for early detection and monitoring of sepsis severity in adult horses.
Read the full abstract on PubMed
Practical Takeaways
- •Plasma syndecan-1 measurement may help veterinarians differentiate septic from non-septic illness in hospitalized adult horses, supporting earlier diagnosis and treatment decisions
- •Elevated syndecan-1 levels indicate endothelial damage and glycocalyx degradation, reflecting disease severity and potentially useful for prognostication in septic cases
- •This biomarker could complement existing SIRS criteria and clinical assessment to identify horses requiring aggressive intensive care management
Key Findings
- •Plasma syndecan-1 concentrations were significantly higher in septic horses (50.73 ± 84.24 μg/ml) compared to healthy (15.69 ± 11.28 μg/ml) and non-septic ill horses (16.88 ± 15.30 μg/ml)
- •No significant difference in syndecan-1 levels between healthy and non-septic ill horses, suggesting specificity for sepsis
- •SIRS scores were highest in septic horses and correlated with elevated syndecan-1 concentrations
- •Syndecan-1 shows potential as a biochemical biomarker for endothelial glycocalyx damage in equine sepsis